Top Ten most popular articles on Pharmafile.com this week
pharmafile | June 22, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | pharma, top ten
The sun is out in the UK, it’s Friday, and the July/August issue of Pharmafocus is going to print. And, of course, it’s time for another run-down of the top ten most popular articles over the last days.
Among our most widely-read stories was Cancer Research UK’s warning that cancer prevalence in UK citizens over 75 is set to almost double by 2035, and the reveal of new data which shows a new blood test for autism diagnosis proved to be 88% effective.
But, swiftly following the news that Prime Minister Theresa May announces £20 billion in funding for the NHS, the most popular story this week is a new report which claims the health service could save £7 billion in five years through the use of new diagnostic tools.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. Purdue culls 350 positions, eradicates sales force
Purdue Pharma has announced that it has axed around 350 employees from the company, a move which also includes the eradication of the remainder of its already-gutted sales force.
9. Sarepta shares surge after gene therapy leads to microdystrophin expression in DMD patients
Shares in Sarepta Therapeutics rocketed by 80% after the company released preliminary data from a Phase 1/2a trial showing that its experimental gene therapy – AAVrh74.MHCK7 – boosted production of a truncated form of a muscle-making protein in three young boys with Duchenne muscular dystrophy (DMD).
8. Kallyope and Novo Nordisk announce obesity and diabetes collaboration
Kallyope and Novo Nordisk have entered into a research collaboration and option agreement to discover novel peptide therapeutics for the treatment of obesity and diabetes.
7. Roche buys out rest of Foundation Medicine for $2.4bn
Roche has clearly seen significant potential in Foundation Medicine’s work in genomics to pay $2.4 billion to take complete ownership of the company.
6. PTC Therapeutics’ results in SMA has Biogen nervous
PTC Therapeutics was able to post data from a Phase 1 trial showing 90% of babies given the treatment showed signs of improvement.
5. NICE turns down Roche’s Perjeta for post-surgery HER2-positive breast cancer
Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the NHS for the treatment of HER2-positive breast cancer after surgery in patients with high risk of disease recurrence.
4. New Jersey attempts to lure Teva HQ with tax incentives
New Jersey is offering a 10-year, $40 million tax incentive package for Teva to relocate its headquarters to Parsippany and, in the process, would manage to gain 1,000 jobs from having the company based in the state.
3. “Extremely promising” blood test for autism impresses with 88% accuracy
A blood test designed to support the clinical determination of whether a child is on the autistic spectrum has been proven to be highly successful and could allow for earlier diagnosis, just one year after the original research was published.
2. Elderly cancer cases to increase 80% by 2035, says CRUK
A new report from Cancer Research UK has indicated that the number of UK citizens over the age of 75 with cancer is predicted to rise by up to 80% by the year 2035.
1. NHS could save £7 billion via new diagnostic techniques
Research commissioned by Innovate UK and the British In Vitro Diagnostics Association (BIVDA) has revealed that the NHS could save over £6.9 billion in five years through quick adoption of new diagnostic tests.
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
